Niagen Bioscience (NAGE) Q4 2019 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2019 earnings summary
19 Nov, 2026Executive summary
Q4 net sales rose 44% YoY to $13.1M; FY 2019 sales increased 47% to $46.3M, led by TRU NIAGEN.
FY 2019 exceeded guidance across key metrics, excluding the $2.2M Elysium receivable write-off.
Financial highlights
Q4 operating loss was $8.9M, including $2.2M of non-cash bad debt expense; excluding that item, operating loss was $6.7M.
FY operating loss was $31.3M reported and $29.1M excluding bad debt, a $4.1M improvement YoY on the latter basis.
FY net loss was $32.1M; Adjusted EBITDA excluding legal expense was a loss of $8.8M, improving $7.4M YoY.
Outlook and guidance
2020 outlook: strong top-line growth, with moderate coronavirus impact in Q1; gross margin and Adjusted EBITDA excluding legal expected to improve.
Selling, marketing and advertising expense expected to rise $3–5M in absolute dollars but decline as a share of sales; G&A expected to rise $1–2M in absolute dollars.
Growth drivers include U.S. e-commerce, new markets including the U.K. and Australia, new platforms, returning customers, product cost savings and supply-chain efficiencies.
Cash-flow break-even framework remains unchanged; near-term operating expenses may rise due to litigation, with supply-chain savings targeted to support gross margins slightly above 60%.
Latest events from Niagen Bioscience
- TRU NIAGEN drove 49% FY sales growth, while losses widened and break-even remained a 2019/20 target.NAGE
Q4 2018 - Q4 growth and stronger margins advanced the path toward break-even.NAGE
Q4 2020 - Consumer expansion and rare-disease development anchor a four-part growth strategy.NAGE
A.G.P. Virtual Consumer Showcase - A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Q3 sales fell 20% as investment and new launches targeted future growth.NAGE
Q3 2026 - Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGE
LD Micro 20th Annual Main Event Conference - Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE
17th Annual Midwest IDEAS Conference - Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGE
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches.NAGE
Q2 2026